首页> 美国卫生研究院文献>Drug Design Development and Therapy >Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients
【2h】

Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients

机译:纳米粒子白蛋白结合紫杉醇在晚期乳腺癌中的前瞻性研究:紫杉烷预处理患者的临床结果和生物学观察

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundThere is a deep need to improve the care of metastatic breast cancer (MBC) patients, since even today it remains an incurable disease. Taxanes are considered the most effective cytotoxic drugs for the treatment of MBC, both in monotherapy and in combined schedules, but the need for synthetic solvents contributes to the severe toxicities and may have a negative impact on the efficacy. Nanoparticle albumin-bound paclitaxel (Nab-paclitaxel) is a colloidal suspension of paclitaxel and human serum albumin initially developed to avoid the toxicities associated with conventional taxanes.
机译:背景技术迫切需要改善转移性乳腺癌(MBC)患者的护理,因为即使在今天,它仍然是无法治愈的疾病。紫杉烷在单一疗法和联合疗法中均被认为是治疗MBC的最有效的细胞毒性药物,但对合成溶剂的需求会导致严重的毒性,并且可能对疗效产生负面影响。纳米颗粒结合白蛋白的紫杉醇(Nab-紫杉醇)是紫杉醇和人血清白蛋白的胶体悬浮液,最初是为避免与常规紫杉烷类药物相关的毒性而开发的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号